Safety and preliminary efficacy on cognitive performance and adaptive functionality of epigallocatechin gallate (EGCG) in children with Down syndrome. A randomized phase Ib clinical trial (PERSEUS study).
Cieuta-Walti C, Cuenca-Royo A, Langohr K, Rakic C, López-Vílchez MÁ, Lirio J, González-Lamuño Leguina D, González TB, García JG, Roure MR, Aldea-Perona A, Forcano L, Gomis-Gonzalez M, Cés SV, Lacaille F, Ravel A, Mircher C, Walti H, Janel N, Dairou J, Lévy M, Durand S, Dierssen M, Sacco S, Fornell RT; PERSEUS Study Group.
Cieuta-Walti C, et al.
Genet Med. 2022 Oct;24(10):2004-2013. doi: 10.1016/j.gim.2022.06.011. Epub 2022 Aug 11.
Genet Med. 2022.
PMID: 35951014
Free article.
Clinical Trial.
PURPOSE: Although some caregivers are using epigallocatechin gallate (EGCG) off label in hopes of improving cognition in young adults with Down syndrome (DS), nothing is known about its safety, tolerability, and efficacy in the DS pediatric population. We aimed to e …
PURPOSE: Although some caregivers are using epigallocatechin gallate (EGCG) off label in hopes of improving cognition in young …